Tempus AI
AI-enabled precision medicine.
About Tempus AI
Clinical and molecular data platform that helps oncologists tailor cancer treatment to each patient. Public via 2024 IPO.
Pitch deck breakdown
How Tempus AI would pitch themselves.
Target customer
Customers in the Tempus AI space — typically operators or teams running into the problem this product solves.
Problem they solve
Clinical and molecular data platform that helps oncologists tailor cancer treatment to each patient. Public via 2024 IPO. The category has historically been served by tools that miss the modern workflow this product is built around.
Key differentiator
Tempus AI differentiates on ai-enabled precision medicine. Backed by Baillie Gifford + T. Rowe Price — the company has resources + validation to compound this thesis. Founded by Eric Lefkofsky.
Go-to-market strategy
Late-stage scale — global enterprise sales force, channel + reseller partnerships, vertical-specific go-to-market motions. Focus on land-and-expand within existing accounts + international expansion.
Company facts
- Category
- Other
- Funding stage
- IPO 2024
- Total raised
- Public (NASDAQ: TEM)
- Founded
- 2015
- Team size
- 1001+
- HQ
- Chicago
- Country
- United States
- Website
- tempus.com
Founders of Tempus AI
- Eric Lefkofsky
Investors backing Tempus AI
- Baillie Gifford
- T. Rowe Price
Frequently asked questions
What does Tempus AI do?
Clinical and molecular data platform that helps oncologists tailor cancer treatment to each patient. Public via 2024 IPO.
Where is Tempus AI based?
Tempus AI is based in Chicago, United States.
When was Tempus AI founded?
Tempus AI was founded in 2015.
How much has Tempus AI raised?
Tempus AI has raised Public (NASDAQ: TEM) in their IPO 2024 round.
Who founded Tempus AI?
Tempus AI was founded by Eric Lefkofsky.
Who has invested in Tempus AI?
Tempus AI is backed by Baillie Gifford, T. Rowe Price.